These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 7018667)

  • 1. Isolation of a nontoxic lipid A fraction containing tumor regression activity.
    Takayama K; Ribi E; Cantrell JL
    Cancer Res; 1981 Jul; 41(7):2654-7. PubMed ID: 7018667
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhancement of endotoxic shock by N-acetylmuramyl-L-alanyl-(L-seryl)-D-isoglutamine (muramyl dipeptide).
    Ribi EE; Cantrell JL; Von Eschen KB; Schwartzman SM
    Cancer Res; 1979 Nov; 39(11):4756-9. PubMed ID: 115579
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lipid A and immunotherapy.
    Ribi E; Cantrell JL; Takayama K; Qureshi N; Peterson J; Ribi HO
    Rev Infect Dis; 1984; 6(4):567-72. PubMed ID: 6382555
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regression of line-10 hepatocellular carcinoma by a less toxic cord factor analogue combined with L18-MDP or synthetic lipid A analogues.
    Ishida H; Saiki I; Saito S; Hasegawa A; Kiso M; Azuma I
    Vaccine; 1988 Oct; 6(5):440-4. PubMed ID: 3195200
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structural requirements of endotoxic glycolipid for antitumor and toxic activity.
    Amano K; Ribi E; Cantrell JL
    J Biochem; 1983 May; 93(5):1391-9. PubMed ID: 6350277
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activation of murine Kupffer cell tumoricidal activity by liposomes containing lipophilic muramyl dipeptide.
    Phillips NC; Rioux J; Tsao MS
    Hepatology; 1988; 8(5):1046-50. PubMed ID: 2971013
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Purification and structural determination of nontoxic lipid A obtained from the lipopolysaccharide of Salmonella typhimurium.
    Qureshi N; Takayama K; Ribi E
    J Biol Chem; 1982 Oct; 257(19):11808-15. PubMed ID: 6749846
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined effects of synthetic lipid A analogs or bacterial lipopolysaccharide with glucosaminylmuramyl dipeptide on antitumor activity against Meth A fibrosarcoma in mice.
    Shimizu T; Iwamoto Y; Yanagihara Y; Ikeda K; Achiwa K
    Int J Immunopharmacol; 1992 Nov; 14(8):1415-20. PubMed ID: 1464473
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endotoxin from Fusobacterium necrophorum of bovine hepatic abscess origin.
    Warner JF; Fales WH; Sutherland RC; Teresa GW
    Am J Vet Res; 1975 Jul; 36(7):1015-9. PubMed ID: 1147341
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjuvant activity of 6-O-mycoloyl derivatives of N-acetylmuramyl-L-seryl-D-isoglutamine and related compounds in mice and guinea pigs.
    Uemiya M; Sugimura K; Kusama T; Saiki I; Yamawaki M; Azuma I; Yamamura Y
    Infect Immun; 1979 Apr; 24(1):83-9. PubMed ID: 313372
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Separation and characterization of toxic and nontoxic forms of lipid A.
    Takayama K; Qureshi N; Ribi E; Cantrell JL
    Rev Infect Dis; 1984; 6(4):439-43. PubMed ID: 6474003
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regression of line-10 hepatocarcinoma with synthetic quinonyl muramyl dipeptide in strain-2 guinea pigs.
    Tanio Y; Souma H; Tokushima Y; Yamamura Y; Azuma I
    Gan; 1983 Apr; 74(2):192-5. PubMed ID: 6862142
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Two adjuvant-active muramyl dipeptide analogs induce differential production of lymphocyte-activating factor and a factor causing distress in guinea pigs.
    Byars NE
    Infect Immun; 1984 May; 44(2):344-50. PubMed ID: 6609127
    [TBL] [Abstract][Full Text] [Related]  

  • 14. On the pyrogenic action of intravenous lipid A in rabbits.
    Kenedi E; Laburn H; Mitchell D; Ross FP
    J Physiol; 1982 Jul; 328():361-70. PubMed ID: 7131316
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regression of tumors in guinea pigs after treatment with synthetic muramyl dipeptides and trehalose dimycolate.
    McLaughlin CA; Schwartzman SM; Horner BL; Jones GH; Moffatt JG; Nestor JJ; Tegg D
    Science; 1980 Apr; 208(4442):415-6. PubMed ID: 7189295
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bacterial cell surface biological response modifiers and their synthetic counterparts.
    Kotani S
    Adv Exp Med Biol; 1992; 319():145-64. PubMed ID: 1414590
    [No Abstract]   [Full Text] [Related]  

  • 17. Adjuvant activity of synthetic 6-O-"mycoloyl"-N-acetylmuramyl-L-alanyl-D-isoglutamine and related compounds.
    Azuma I; Sugimura K; Yamawaki M; Uemiya M; Kusumoto S; Okada S; Shiba T; Yamamura Y
    Infect Immun; 1978 Jun; 20(3):600-7. PubMed ID: 97234
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of immunomodulatory activities in mice and guinea pigs of a synthetic desmuramyl peptidolipid triglymyc.
    Leclerc CD; Audibert FM; Chedid LA; Deriaud EJ; Masihi NK; Lederer E
    Infect Immun; 1984 Mar; 43(3):870-5. PubMed ID: 6698611
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevention of experimental endotoxin shock by a monocyte activator.
    Passlick B; Labeta MO; Izbicki JR; Ostertag P; Löffler T; Siebeck M; Pichlmeier U; Schweiberer L; Ziegler-Heitbrock HW
    Antimicrob Agents Chemother; 1995 Nov; 39(11):2535-40. PubMed ID: 8585740
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antitumor activity on line 10 hepatoma in strain 2 guinea pigs and pharmaceutical properties of quinonyl-MDP preparations.
    Azuma I; Ogawa Y; Igari Y; Ukei S; Yamamura Y
    Methods Find Exp Clin Pharmacol; 1986 Jan; 8(1):15-8. PubMed ID: 3702541
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.